Cempra Pharmaceuticals

News - Cempra Pharmaceuticals

Taksta(TM) (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients

2011-11-03 07:00:00

ANAHEIM, Calif., Nov.

Additional Data on the Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA)

2011-10-20 07:00:00

BOSTON, Oct.

Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

2011-09-16 06:00:00

CHICAGO, Sept.

Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)

2011-09-15 06:00:00

CHAPEL HILL, N.C., Sept.

Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial

2011-05-07 04:30:00

CHAPEL HILL, N.C., May 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic (PK) profile at IV doses up to 800 mg.

More News (26 articles) »

News - Cempra Pharmaceuticals

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health